3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Motor Activity
9
Neoplasms
6
Pancreatic Neoplasms
3
Lung Neoplasms
3
Breast Neoplasms
3
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Peripheral Nervous System Diseases
1
Neurocognitive Disorders
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cognitive Dysfunction
1
Interventions
Bevacizumab
28
Fluorouracil
24
Oxaliplatin
22
Specimen Handling
21
Leucovorin
21
Cetuximab
19
pembrolizumab
14
Biopsy
14
Magnetic Resonance Spectroscopy
12
Irinotecan
12
Folfox protocol
8
Nivolumab
7
Capecitabine
7
balstilimab
6
Panitumumab
6
IFL protocol
6
HMPL-013
5
trifluridine tipiracil drug combination
4
fludarabine
4
dehydroftorafur
4
atezolizumab
4
X-Rays
4
Standard of Care
4
Pemetrexed
4
Immunoglobulin G
4
Disulfides
4
Cyclophosphamide
4
Cisplatin
4
Carboplatin
4
encorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Exercise
×
30 days
×
Clear all
NCT06938971
2026-05-13
REACH
Rigshospitalet, Denmark
Phase NA
Recruiting
150 enrolled